Bristol-Myers Squibb & Eli Lilly

Cetuximab-erbitux

“Cetuximab” is the Drug / Molecule content in “Erbitux” Erbitux is a targeted therapy that targets and binds to the epidermal growth factor receptors (EGFR) on the surface of the cell. EGFR is found on the surface of many normal and cancer cells. By binding to these receptors, Erbitux blocks an important pathway that promotes cell division this results in inhibition of cell growth and apoptosis.

Details
Specification

Indication

Erbitux is used for treatment of metastatic colorectal cancer and squamous cell carcinoma of the head and neck.

Note

"Cetuximab" distributed under the trade name "Erbitux" in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution.